Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Rapidly declining memory in people with cognitive impairment may indicate stage before Alzheimer's disease

Memory and thinking skills may decline rapidly for people who have mild cognitive impairment, which is the stage before Alzheimer's disease when people have mild memory problems but no dementia symptoms, and even more rapidly when dementia begins, which is when Alzheimer's disease is usually diagnosed. The research is published in the March 23, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

23 Mar 2010

You and your baby may need vitamin D supplementation says research

This report appeared in the respected Journal Pediatrics this week. There has been growing awareness regarding deficiency of Vitamin D in children and adults. This vitamin is important for healthy bones, immunity and other bodily processes. In children inadequacy of this vitamin in diet may lead to bone damage, rickets, repeated infections and heart disease in later life.

23 Mar 2010

KMI announces strategic distribution agreement with Mobility to market stroke therapy devices

Kinetic Muscles Inc., a leading developer of stroke therapy technology, today announced a strategic distribution agreement with Mobility Research, also of Tempe, that will allow Mobility to market KMI’s products in specific international markets.

23 Mar 2010

Ultraviolet portion of sunlight may play bigger role in controlling MS: Study

For more than 30 years, scientists have known that multiple sclerosis (MS) is much more common in higher latitudes than in the tropics. Because sunlight is more abundant near the equator, many researchers have wondered if the high levels of vitamin D engendered by sunlight could explain this unusual pattern of prevalence.

23 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Acorda Therapeutics, Inc. today announced that the Company has submitted applications to extend patent protection for AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg to the United States Patent and Trademark Office.

22 Mar 2010

Americans to join in Purple Day campaign to support epilepsy awareness

Members of the U.S. House and Senate, children in schools across the country, and employees of workplaces nationwide will wear purple to support epilepsy awareness on March 26. Thousands of Americans will also join the campaign by hosting Purple Day activities in their regions.

22 Mar 2010

AARDA launches campaign on family AQ

In honor of the designation of March as National Autoimmune Disease Awareness Month by the U.S. Senate on March 4, 2010, the American Autoimmune Related Diseases Association (AARDA) wants to help you learn your family's AQ. AQ is a play on IQ that stands for Autoimmune Quotient. It's about knowing how likely you or a loved one is to develop an autoimmune disease, based on the prevalence of these diseases and your family history. The campaign features AARDA National Spokesperson and Actress Kellie Martin, best known for her memorable roles on "E.R." and "Life Goes On."

22 Mar 2010

Mayo Clinic co-led research finds first gene linked to lung cancer in "never smokers"

A five-center collaborative study that scanned the genomes of thousands of "never smokers" diagnosed with lung cancer as well as healthy never smokers has found a gene they say could be responsible for a significant number of those cancers.

22 Mar 2010

As reform hangs in balance, policy benefits continue to be discussed

NPR reports on the immediate effects of the proposed health care bill, and that Congressional Democrats are focusing on those benefits in messages to constituents. "The White House is trying to shift the conversation away from the messy legislative process — which Republicans are keying on — and instead focus on what the health care overhaul would do for families and businesses."

19 Mar 2010

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

Manitobans with wet age-related macular degeneration (AMD) received a dose of good news. The Manitoba government announced that Lucentis (ranibizumab injection) will soon be funded through a centralized vision program, effective June 1, 2010.

18 Mar 2010

New book exposes the ignored causes of three major life-threatening and chronic diseases

In his newest book, "Overlooked Causes and the Prevention: Cancer, Cardiovascular Heart Disease, Multiple Sclerosis" (published by AuthorHouse), author Arthur Douglass Alexander III exposes, delineates and documents the sometimes overlooked and often ignored causes of three major life-threatening and chronic diseases: cancer, cardiovascular disease and multiple sclerosis.

18 Mar 2010

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported positive preliminary results from a Phase Ib clinical trial to evaluate the safety and efficacy of MN-221 in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD). There were no clinically significant safety concerns noted. Preliminary results demonstrated clinically significant improvements in percent change in forced expiratory volume in one second (FEV(1)).

18 Mar 2010

Scientists discover switch mechanism that controls cells' trafficking system

Scientists have identified a mechanism that switches on an extremely important process for the proper functioning and survival of our body's cells. Specifically, the fast-track transportation pathway of 'cargo' to and from the surface of the cell.

18 Mar 2010

Beneficial impact of vitamin D could alleviate symptoms and treat MS

Glasgow GP Dr Tom Gilhooly is at the forefront of an exciting new treatment for sufferers of MS. He comments ‘Scotland has the greatest incidence of Multiple Sclerosis in the world – and has more to gain than any other country from new developments such as CCSVI.’

18 Mar 2010

Methamphetamine abuse during pregnancy leads to structural abnormalities in brain of children

It has long been known that alcohol exposure is toxic to the developing fetus and can result in lifelong brain, cognitive and behavioral problems. Now, a new report out of UCLA shows that the effects of prenatal methamphetamine exposure - or worse, a combination of methamphetamine and alcohol - may be even more damaging.

17 Mar 2010

CogniFit Personal Coach brain training software improves cognitive function of MS patients

CogniFit™, Inc., a leading maker of Brain Fitness Software (www.cognifit.com), announced a new, independent study that shows CogniFit Personal Coach brain training software improves the cognitive function and skills of Multiple Sclerosis (MS) patients.

16 Mar 2010

Liquid CMO seeks osteoarthritis and fibromyalgia patients for pilot study in Phoenix

Makers of a new liquid natural supplement formulation of Cetyl-Myristoleate (CMO) are seeking osteoarthritis and fibromyalgia patients for a pilot study in Phoenix beginning Monday, April 12, 2010.

16 Mar 2010

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

GTC Biotherapeutics, Inc. today reported its financial results for the fourth quarter and fiscal year ended January 3, 2010. The total net loss for the fourth quarter was $1.7 million, or $0.09 per share, compared with $6.2 million, or $0.60 per share, for the fourth quarter of 2008. The total net loss for 2009 was $27.9 million, or $2.18 per share, compared to $22.7 million, or $2.31 per share, for 2008.

12 Mar 2010

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

UCB today announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.

12 Mar 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Rapidly declining memory in people with cognitive impairment may indicate stage before Alzheimer's disease

You and your baby may need vitamin D supplementation says research

KMI announces strategic distribution agreement with Mobility to market stroke therapy devices

Ultraviolet portion of sunlight may play bigger role in controlling MS: Study

ChemoCentryx undertakes Phase II clinical trial of CCX140

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Americans to join in Purple Day campaign to support epilepsy awareness

AARDA launches campaign on family AQ

Mayo Clinic co-led research finds first gene linked to lung cancer in "never smokers"

As reform hangs in balance, policy benefits continue to be discussed

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

New book exposes the ignored causes of three major life-threatening and chronic diseases

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

Scientists discover switch mechanism that controls cells' trafficking system

Beneficial impact of vitamin D could alleviate symptoms and treat MS

Methamphetamine abuse during pregnancy leads to structural abnormalities in brain of children

CogniFit Personal Coach brain training software improves cognitive function of MS patients

Liquid CMO seeks osteoarthritis and fibromyalgia patients for pilot study in Phoenix

GTC Biotherapeutics reports total net loss of $1.7M for fourth-quarter 2009

Phase III clinical study: Vimpat demonstrates fewer partial-onset seizures versus placebo in adults with epilepsy

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Newsletters you may be interested in